Biotech News Recap: Pressure On Shares Of Novartis Continues Following Zolgensma Patient Death [Seeking Alpha]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Seeking Alpha
Biotech News Recap: Pressure On Shares Of Novartis Continues Following Zolgensma Patient Death Summary While interim data from the phase 2 STR1VE trial of Zolgensma in SMA Type 1 was encouraging, it was overshadowed by the death of a second patient. It remains to be seen what steps the FDA takes. May PDUFA date is approaching. Previously Novartis shelled out a whopping $8.7 billion to gain control of the treatment. Ionis Pharmaceuticals (and partner Biogen) would benefit from any setbacks for their competitor, as previously Spinraza sales were thought to face a decline upon Zolgensma's arrival to the market. Gritstone Oncology received a boost from positive FDA guidance which accelerates timeline for its SLATE phase 1 study. GlycoMimetics received more validation of its approach from publication of a paper in Nature Cell Biology. Eli Lilly's Taltz (ixekizumab) achieved primary and all major secondary endpoints in COAST-X Phase 3 study for the treatment of nr-axSpA. Novartis ( NVS anno
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $85.00 to $82.00. They now have an "overweight" rating on the stock.MarketBeat
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.MarketBeat
- Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 5/7/24 - Beat
IONS
Sec Filings
- 5/7/24 - Form 4
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- IONS's page on the SEC website